This article is more than 5 years old. Information may no longer be current.

Response to Juvéderm Voluma XC high in midface at 6 months, increased with injection volume

Juvéderm Voluma XC injected into three facial subregions resulted in high responder rates at 6 months, according to recently published study results.

 Researchers studied 235 patients (median age, 56 years; 80.4% women) with midface volume deficit who received Juvéderm Voluma XC (VYC-20L; hyaluronic acid gel containing lidocaine, Allergan) in at least one of three facial subregions, zygomaticomalar, anteromedial cheek and submalar. At 30 days after initial treatment, touch-up treatment was available.

At least 1 point reduction (improvement) in Mid-Face Volume Deficit Scale (MFVDS) score derived from month 6 assessment scores compared with baseline pre-treatment assessments was used to define as response in each facial subregion. Patient satisfaction and safety also were measured.

Responder rates at month 6 were 75.5% for zygomaticomalar region, 83.2% for anteromedial cheek and 76.9% for submalar region. Increasing injection volume in each subregion resulted in in higher responder rates. Correction durations of 15 to 24 months were observed in similar injection volumes of approximately equal to 2.0 mL total of VYC-20L, including 24 months in the anteromedial cheek, 19 months for zygomaticomalar subregion and 15 months for the submalar subregion. No treatment-site adverse events were observed.

“The data show that Month 6 MFVDS responder rates were high … in each subfacial subregion, and responder rates generally increased with higher injection quartiles,” the researchers wrote.

“VYC-20L is effective at restoring midface volume, with high subject satisfaction, and acceptable safety profile,” they concluded.  – By Bruce Thiel

Disclosure: Glaser reports serving as a remunerated adviser, consultant and speaker for Allergan, and receiving research grants from Allergan. Please see the study for a full list of other researchers’ relevant financial disclosures.